End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,845 KRW | +4.21% | +1.25% | -29.93% |
Apr. 25 | Noul Announces 2 Clinical Performance Studies At Pan-African Malaria Conference | CI |
2023 | Noul Co., Ltd. Unveils the Result of Malaria Study in Ethiopia and Ghana | CI |
Sales 2022 | 542M 391K | Sales 2023 | 2.73B 1.97M | Capitalization | 150B 108M |
---|---|---|---|---|---|
Net income 2022 | -13.68B -9.88M | Net income 2023 | -16.32B -11.78M | EV / Sales 2022 | 182 x |
Net Debt 2022 | 140M 101K | Net cash position 2023 | 11.81B 8.53M | EV / Sales 2023 | 50.5 x |
P/E ratio 2022 |
-6.92
x | P/E ratio 2023 |
-6.66
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 68.44% |
1 day | +4.21% | ||
1 week | +1.25% | ||
1 month | +23.16% | ||
3 months | -9.54% | ||
6 months | -48.74% | ||
Current year | -29.93% |
Managers | Title | Age | Since |
---|---|---|---|
Chan-Young Im
CEO | Chief Executive Officer | 45 | 15-11-30 |
Ri-Hyeon Kim
DFI | Director of Finance/CFO | 42 | 20-04-30 |
Dong-Young Lee
CTO | Chief Tech/Sci/R&D Officer | 45 | 15-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chan-Young Im
CEO | Chief Executive Officer | 45 | 15-11-30 |
Dong-Young Lee
CTO | Chief Tech/Sci/R&D Officer | 45 | 15-11-30 |
Kyung-Hwan Kim
BRD | Director/Board Member | 45 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2,845 | +4.21% | 547,331 |
24-05-30 | 2,730 | +0.92% | 233,647 |
24-05-29 | 2,705 | -1.81% | 294,703 |
24-05-28 | 2,755 | -1.43% | 277,542 |
24-05-27 | 2,795 | -0.53% | 388,210 |
End-of-day quote Korea S.E., May 30, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-29.93% | 76.01M | |
-38.56% | 8.39B | |
+0.18% | 3.32B | |
+9.29% | 2.48B | |
-18.21% | 2.06B | |
-24.57% | 1.59B | |
+32.37% | 1.15B | |
-7.64% | 704M | |
+8.42% | 678M | |
-29.59% | 508M |
- Stock Market
- Equities
- A376930 Stock